<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD09050000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P00751</UniProt_ID>
  <Seq_Length>764</Seq_Length>
  <Molecule_Weight>85533</Molecule_Weight>
  <KEGG_ID>hsa:629</KEGG_ID>
  <Orthology_ID>K01335</Orthology_ID>
  <Function_Summary>Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes.</Function_Summary>
  <Catalytic_Mechanism>Cleavage of Arg-|-Ser bond in complement component C3 alpha-chain to yield C3a and C3b, and Arg-|-Xaa bond in complement component C5 alpha-chain to yield C5a and C5b.</Catalytic_Mechanism>
  <Pfam_ID>PF00084:Sushi@@PF00089:Trypsin@@PF00092:VWA</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Complement factor B Bb fragment</Alias>
      <Alias>Properdin factor B</Alias>
      <Alias>PBF2</Alias>
      <Alias>C3/C5 convertase</Alias>
      <Alias>GBG</Alias>
      <Alias>Glycine-rich beta glycoprotein</Alias>
      <Alias>Complement factor B Ba fragment</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004252</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine).</Detail>
      <Keyword>Serine-type peptidase activity</Keyword>
      <Ontology_ID>GO:0008236</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any component or product of the complement cascade.</Detail>
      <Keyword>Complement binding</Keyword>
      <Ontology_ID>GO:0001848</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>242</Position>
      <Original>Ile</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>533</Position>
      <Original>Lys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>203</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>323</Position>
      <Original>Lys</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>252</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>736</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>323</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>32</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>28</Position>
      <Original>Trp</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>458</Position>
      <Original>Met</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>32</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>9</Position>
      <Original>Leu</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>565</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>166</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>651</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>286</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>28</Position>
      <Original>Trp</Original>
      <Variation>Arg</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.</Detail>
      <Keyword>Proteolysis</Keyword>
      <Ontology_ID>GO:0006508</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the activation of any of the steps of the alternative pathway of the complement cascade which allows for the direct killing of microbes and the regulation of other immune processes.</Detail>
      <Keyword>Complement activation, alternative pathway</Keyword>
      <Ontology_ID>GO:0006957</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.</Detail>
      <Keyword>Innate immune response</Keyword>
      <Ontology_ID>GO:0045087</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of complement activation.</Detail>
      <Keyword>Regulation of complement activation</Keyword>
      <Ontology_ID>GO:0030449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Protein involved in immunity, any immune system process that functions in the response of an organism to a potential internal or invasive threat. The vertebrate immune system is formed by the innate immune system (composed of phagocytes, complement, antimicrobial peptides, etc) and by the adaptive immune system which consists of T- and B-lymphocytes.</Detail>
      <Keyword>Immunity</Keyword>
      <Ontology_ID>KW-0391</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MGSNLSPQLCLMPFILGLLSGGVTTTPWSLARPQGSCSLEGVEIKGGSFRLLQEGQALEYVCPSGFYPYPVQTRTCRSTGSWSTLKTQDQKTVRKAECRAIHCPRPHDFENGEYWPRSPYYNVSDEISFHCYDGYTLRGSANRTCQVNGRWSGQTAICDNGAGYCSNPGIPIGTRKVGSQYRLEDSVTYHCSRGLTLRGSQRRTCQEGGSWSGTEPSCQDSFMYDTPQEVAEAFLSSLTETIEGVDAEDGHGPGEQQKRKIVLDPSGSMNIYLVLDGSDSIGASNFTGAKKCLVNLIEKVASYGVKPRYGLVTYATYPKIWVKVSEADSSNADWVTKQLNEINYEDHKLKSGTNTKKALQAVYSMMSWPDDVPPEGWNRTRHVIILMTDGLHNMGGDPITVIDEIRDLLYIGKDRKNPREDYLDVYVFGVGPLVNQVNINALASKKDNEQHVFKVKDMENLEDVFYQMIDESQSLSLCGMVWEHRKGTDYHKQPWQAKISVIRPSKGHESCMGAVVSEYFVLTAAHCFTVDDKEHSIKVSVGGEKRDLEIEVVLFHPNYNINGKKEAGIPEFYDYDVALIKLKNKLKYGQTIRPICLPCTEGTTRALRLPPTTTCQQQKEELLPAQDIKALFVSEEEKKLTRKEVYIKNGDKKGSCERDAQYAPGYDKVKDISEVVTPRFLCTGGVSPYADPNTCRGDSGGPLIVHKRSRFIQVGVISWGVVDVCKNQKRQKQVPAHARDFHINLFQVLPWLKEKLQDEDLGFL</Protein_Seq>
    <DNA_Seq>GACTTCTGCAGTTTCTGTTTCCTTGACTGGCAGCTCAGCGGGGCCCTCCCGCTTGGATGTTCCGGGAAAGTGATGTGGGTAGGACAGGCGGGGCGAGCCGCAGGTGCCAGAACACAGATTGTATAAAAGGCTGGGGGCTGGTGGGGAGCAGGGGAAGGGAATGTGACCAGGTCTAGGTCTGGAGTTTCAGCTTGGACACTGAGCCAAGCAGACAAGCAAAGCAAGCCAGGACACACCATCCTGCCCCAGGCCCAGCTTCTCTCCTGCCTTCCAACGCCATGGGGAGCAATCTCAGCCCCCAACTCTGCCTGATGCCCTTTATCTTGGGCCTCTTGTCTGGAGGTGTGACCACCACTCCATGGTCTTTGGCCCGGCCCCAGGGATCCTGCTCTCTGGAGGGGGTAGAGATCAAAGGCGGCTCCTTCCGACTTCTCCAAGAGGGCCAGGCACTGGAGTACGTGTGTCCTTCTGGCTTCTACCCGTACCCTGTGCAGACACGTACCTGCAGATCTACGGGGTCCTGGAGCACCCTGAAGACTCAAGACCAAAAGACTGTCAGGAAGGCAGAGTGCAGAGCAATCCACTGTCCAAGACCACACGACTTCGAGAACGGGGAATACTGGCCCCGGTCTCCCTACTACAATGTGAGTGATGAGATCTCTTTCCACTGCTATGACGGTTACACTCTCCGGGGCTCTGCCAATCGCACCTGCCAAGTGAATGGCCGATGGAGTGGGCAGACAGCGATCTGTGACAACGGAGCGGGGTACTGCTCCAACCCGGGCATCCCCATTGGCACAAGGAAGGTGGGCAGCCAGTACCGCCTTGAAGACAGCGTCACCTACCACTGCAGCCGGGGGCTTACCCTGCGTGGCTCCCAGCGGCGAACGTGTCAGGAAGGTGGCTCTTGGAGCGGGACGGAGCCTTCCTGCCAAGACTCCTTCATGTACGACACCCCTCAAGAGGTGGCCGAAGCTTTCCTGTCTTCCCTGACAGAGACCATAGAAGGAGTCGATGCTGAGGATGGGCACGGCCCAGGGGAACAACAGAAGCGGAAGATCGTCCTGGACCCTTCAGGCTCCATGAACATCTACCTGGTGCTAGATGGATCAGACAGCATTGGGGCCAGCAACTTCACAGGAGCCAAAAAGTGTCTAGTCAACTTAATTGAGAAGGTGGCAAGTTATGGTGTGAAGCCAAGATATGGTCTAGTGACATATGCCACATACCCCAAAATTTGGGTCAAAGTGTCTGAAGCAGACAGCAGTAATGCAGACTGGGTCACGAAGCAGCTCAATGAAATCAATTATGAAGACCACAAGTTGAAGTCAGGGACTAACACCAAGAAGGCCCTCCAGGCAGTGTACAGCATGATGAGCTGGCCAGATGACGTCCCTCCTGAAGGCTGGAACCGCACCCGCCATGTCATCATCCTCATGACTGATGGATTGCACAACATGGGCGGGGACCCAATTACTGTCATTGATGAGATCCGGGACTTGCTATACATTGGCAAGGATCGCAAAAACCCAAGGGAGGATTATCTGGATGTCTATGTGTTTGGGGTCGGGCCTTTGGTGAACCAAGTGAACATCAATGCTTTGGCTTCCAAGAAAGACAATGAGCAACATGTGTTCAAAGTCAAGGATATGGAAAACCTGGAAGATGTTTTCTACCAAATGATCGATGAAAGCCAGTCTCTGAGTCTCTGTGGCATGGTTTGGGAACACAGGAAGGGTACCGATTACCACAAGCAACCATGGCAGGCCAAGATCTCAGTCATTCGCCCTTCAAAGGGACACGAGAGCTGTATGGGGGCTGTGGTGTCTGAGTACTTTGTGCTGACAGCAGCACATTGTTTCACTGTGGATGACAAGGAACACTCAATCAAGGTCAGCGTAGGAGGGGAGAAGCGGGACCTGGAGATAGAAGTAGTCCTATTTCACCCCAACTACAACATTAATGGGAAAAAAGAAGCAGGAATTCCTGAATTTTATGACTATGACGTTGCCCTGATCAAGCTCAAGAATAAGCTGAAATATGGCCAGACTATCAGGCCCATTTGTCTCCCCTGCACCGAGGGAACAACTCGAGCTTTGAGGCTTCCTCCAACTACCACTTGCCAGCAACAAAAGGAAGAGCTGCTCCCTGCACAGGATATCAAAGCTCTGTTTGTGTCTGAGGAGGAGAAAAAGCTGACTCGGAAGGAGGTCTACATCAAGAATGGGGATAAGAAAGGCAGCTGTGAGAGAGATGCTCAATATGCCCCAGGCTATGACAAAGTCAAGGACATCTCAGAGGTGGTCACCCCTCGGTTCCTTTGTACTGGAGGAGTGAGTCCCTATGCTGACCCCAATACTTGCAGAGGTGATTCTGGCGGCCCCTTGATAGTTCACAAGAGAAGTCGTTTCATTCAAGTTGGTGTAATCAGCTGGGGAGTAGTGGATGTCTGCAAAAACCAGAAGCGGCAAAAGCAGGTACCTGCTCACGCCCGAGACTTTCACATCAACCTCTTTCAAGTGCTGCCCTGGCTGAAGGAGAAACTCCAAGATGAGGATTTGGGTTTTCTATAAGGGGTTTCCTGCTGGACAGGGGCGTGGGATTGAATTAAAACAGCTGCGACAACAAAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>CFB</Gene_Name>
    <Gene_Alias>BF; BFD</Gene_Alias>
    <Gene_ID>629</Gene_ID>
    <Genbank_ACCN>NM_001710</Genbank_ACCN>
    <Protein_ACCN>NP_001701</Protein_ACCN>
    <HGNC_ID>1037</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/629</Gene_URL>
    <UCSC_ID>uc003nyj.4</UCSC_ID>
    <EMBL_ID>ENSG00000241534</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Hemolytic Uremic Syndrome, Atypical 4</Disease_Name>
      <Disease_Detail>Hemolytic-Uremic Syndrome</Disease_Detail>
      <Disease_DB>HML032</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemolytic_uremic_syndrome_atypical_4?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Retinal Drusen</Disease_Name>
      <Disease_Detail>Retinal Drusen</Disease_Detail>
      <Disease_DB>RTN006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/retinal_drusen?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Age Related Macular Degeneration</Disease_Name>
      <Disease_Detail>Age Related Macular Degeneration</Disease_Detail>
      <Disease_DB>AGR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/age_related_macular_degeneration?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemolytic-Uremic Syndrome</Disease_Name>
      <Disease_Detail>Hemolytic-Uremic Syndrome</Disease_Detail>
      <Disease_DB>HML001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemolytic_uremic_syndrome?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Macular Degeneration, Age-Related, 14, Reduced Risk of</Disease_Name>
      <Disease_Detail>Macular Degeneration</Disease_Detail>
      <Disease_DB>MCL054</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/macular_degeneration_age_related_14_reduced_risk_of?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cfb-Related Atypical Hemolytic-Uremic Syndrome</Disease_Name>
      <Disease_Detail>Cfb-Related Atypical Hemolytic-Uremic Syndrome</Disease_Detail>
      <Disease_DB>CFB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cfb_related_atypical_hemolytic_uremic_syndrome?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dense Deposit Disease</Disease_Name>
      <Disease_Detail>Dense Deposit Disease</Disease_Detail>
      <Disease_DB>DNS007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dense_deposit_disease?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lupus Nephritis</Disease_Name>
      <Disease_Detail>Lupus Nephritis</Disease_Detail>
      <Disease_DB>LPS007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lupus_nephritis?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atypical Hemolytic-Uremic Syndrome</Disease_Name>
      <Disease_Detail>Atypical Hemolytic-Uremic Syndrome</Disease_Detail>
      <Disease_DB>ATY010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atypical_hemolytic_uremic_syndrome?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mumps</Disease_Name>
      <Disease_Detail>Mumps</Disease_Detail>
      <Disease_DB>MMP001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mumps?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>C4b Deficiency</Disease_Name>
      <Disease_Detail>C4b Deficiency</Disease_Detail>
      <Disease_DB>C4B001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/c4b_deficiency?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Choroiditis</Disease_Name>
      <Disease_Detail>Choroiditis</Disease_Detail>
      <Disease_DB>CHR008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/choroiditis?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Multifocal Choroiditis</Disease_Name>
      <Disease_Detail>Multifocal Choroiditis</Disease_Detail>
      <Disease_DB>MLT035</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/multifocal_choroiditis?search=CFB#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Complement Factor B Deficiency</Disease_Name>
      <Disease_Detail>Complement Factor B Deficiency</Disease_Detail>
      <Disease_DB>CMP063</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/complement_factor_b_deficiency?search=CFB#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Cobra Venom Factor (CVF) in complex with human factor B</PDB_Title>
      <PDB_ID>3HRZ</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HRZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex</PubMed_Title>
      <Author>Janssen, B.J., et al.</Author>
      <Journal>Embo J.(2009)28:2469-2478</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19574954?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Complement factor B</PDB_Title>
      <PDB_ID>2OK5</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OK5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Factor B structure provides insights into activation of the central protease of the complement system.</PubMed_Title>
      <Author>Milder, F.J., et al.</Author>
      <Journal>Nat.Struct.Mol.Biol.(2007)14:224-228</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17310251?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>C3 CONVERTASE (C3BBB) STABILIZED BY SCIN</PDB_Title>
      <PDB_ID>2WIN</PDB_ID>
      <Resolution>3.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WIN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and Functional Implications of the Alternative Complement Pathway C3 Convertase Stabilized by a Staphylococcal Inhibitor.</PubMed_Title>
      <Author>Rooijakkers, S.H., et al.</Author>
      <Journal>Nat.Immunol.(2009)10:721-727</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19503103?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Cobra Venom Factor (CVF) in complex with human factor B</PDB_Title>
      <PDB_ID>3HS0</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HS0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex</PubMed_Title>
      <Author>Janssen, B.J., et al.</Author>
      <Journal>Embo J.(2009)28:2469-2478</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19574954?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Complement C3b in Complex with Factor B</PDB_Title>
      <PDB_ID>2XWJ</PDB_ID>
      <Resolution>4.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2XWJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of C3B in Complex with Factors B and D Give Insight Into Complement Convertase Formation.</PubMed_Title>
      <Author>Forneris, F., et al.</Author>
      <Journal>Science(2010)330:1816</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21205667?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Analysis of the Bb segment of Factor B</PDB_Title>
      <PDB_ID>1RRK</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RRK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase.</PubMed_Title>
      <Author>Ponnuraj, K., et al.</Author>
      <Journal>Mol.Cell(2004)14:17-28</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15068800?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Analysis of the Bb segment of Factor B complexed with Di-isopropyl-phosphate (DIP)</PDB_Title>
      <PDB_ID>1RS0</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RS0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase.</PubMed_Title>
      <Author>Ponnuraj, K., et al.</Author>
      <Journal>Mol.Cell(2004)14:17-28</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15068800?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Analysis of the Bb segment of Factor B complexed with 4-guanidinobenzoic acid</PDB_Title>
      <PDB_ID>1RTK</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RTK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase.</PubMed_Title>
      <Author>Ponnuraj, K., et al.</Author>
      <Journal>Mol.Cell(2004)14:17-28</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15068800?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>FACTOR B SERINE PROTEASE DOMAIN</PDB_Title>
      <PDB_ID>1DLE</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DLE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>New structural motifs on the chymotrypsin fold and their potential roles in complement factor B.</PubMed_Title>
      <Author>Jing, H., et al.</Author>
      <Journal>EMBO J.(2000)19:164-173</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10637221?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>A domain of Factor B</PDB_Title>
      <PDB_ID>1Q0P</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Q0P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of the A Domain from Complement Factor B Reveals an Integrin-like Open Conformation.</PubMed_Title>
      <Author>Bhattacharya, A.A., et al.</Author>
      <Journal>STRUCTURE(2004)12:371-378</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15016353?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Complement C3b in complex with Factors B and D</PDB_Title>
      <PDB_ID>2XWB</PDB_ID>
      <Resolution>3.49</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2XWB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structures of C3B in Complex with Factors B and D Give Insight Into Complement Convertase Formation.</PubMed_Title>
      <Author>Forneris, F., et al.</Author>
      <Journal>Science(2010)330:1816</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21205667?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05150</Pathway_ID>
      <Pathway_Title>Staphylococcus aureus infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04610</Pathway_ID>
      <Pathway_Title>Complement and coagulation cascades</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.ia.b.c.dj.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1dle</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Open-Close</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.4.21.47</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/21/47.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>